Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Chapter Forty Seven - Aspirin
from Treatment
Published online by Cambridge University Press: 13 December 2022
Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Summary
Ancient medical practitioners believed in the “doctrine of signatures,” which stated that natural objects that resembled parts of the body could cure diseases affecting those parts. The eyebright plant was used to cure eye diseases due to the similitude of its flowers to blue eyes. The famous Swiss physician Paracelsus was a proponent of this doctrine and stated, “Nature marks each growth, according to its curative benefit.” Herbs were believed to have particular “signatures” given by God for people to identify and use. Although this doctrine had no scientific basis, it led to the discovery of a drug widely used today [1].
- Type
- Chapter
- Information
- Stories of StrokeKey Individuals and the Evolution of Ideas, pp. 447 - 454Publisher: Cambridge University PressPrint publication year: 2022
References
Notes and References
Doctrine of signatures. Science Museum.org. Available at http://broughttolife.sciencemuseum.org.uk/broughttolife/techniques/doctrine.Google Scholar
A history of aspirin. Pharmaceutical Journal. Available at www.pharmaceutical-journal.com/news-and-analysis/infographics/a-history-of-aspirin/20066661.article.Google Scholar
Stone, E. XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire. Philos. Trans. 1763 Jan 1;53:195–200.Google Scholar
Jack, DB. One hundred years of aspirin. Lancet Lond. Engl. 1997 Aug 9;350(9075):437–439.CrossRefGoogle ScholarPubMed
Pearce, JMS. The controversial story of aspirin. World Neurology. December 2, 2014. Available at https://worldneurologyonline.com/article/controversial-story-aspirin/.Google Scholar
Buchanan, WW, Kean, WF. The treatment of acute rheumatism by salicin, by T. J. Maclagan – The Lancet, 1876. J. Rheumatol. 2002 Jun 1;29(6):1321–1323.Google Scholar
Snead, MW, Aikawa, JK. T. J. Maclagan and the treatment of rheumatic fever with salicin. AMA Arch. Intern. Med. 1958 May 1;101(5):997–1004.Google Scholar
Malverde, J. How aspirin turned hero: Heroin, Bayer and Heinrich Dreser. Democratic Underground. Available at www.democraticunderground.com/11701737.Google Scholar
Lichterman, BL. Aspirin: The story of a wonder drug. BMJ 2004 Dec 11;329(7479):1408.CrossRefGoogle Scholar
Miner, J, Hoffhines, A. The discovery of aspirin’s antithrombotic effects. Tex. Heart Inst. J. 2007;34(2):179–186.Google Scholar
Craven, LL. Coronary thrombosis can be prevented. J. Insurance Med. 1950;5:47–48.Google ScholarPubMed
Craven, LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss. Valley Med. J. 1953;75:38–44.Google ScholarPubMed
Craven, LL. Prevention of coronary and cerebral thrombosis. Miss. Valley Med. J. 1956;78:213–215.Google Scholar
Weiss, HJ, Aledort, LM, Kochwa, S. The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest. 1968;47:2169–2180.Google Scholar
Vane, JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971;231:232–235.Google Scholar
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.Google Scholar
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.Google Scholar
Bell, AD, Roussin, A, Cartier, R, Chan, WS, Douketis, JD, Gupta, A, Kraw, ME, Lindsay, TF, Love, MP, Pannu, N, Rabasa-Lhoret, R, Shuaib, A, Teal, P, Théroux, P, Turpie, AG, Welsh, RC, Tanguay, JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can. J. Cardiol. 2011;27:208–221.CrossRefGoogle Scholar
Graham, I, Atar, D, Borch-Johnson, K, et al. for the ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:1–45.CrossRefGoogle ScholarPubMed
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009;150:396–404.Google Scholar
Vandvik, PO, Lincoff, AM, Core, JM, et al. for American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e637S–e668S.CrossRefGoogle ScholarPubMed
Mundall, J, Quintero, P, von Kaulla, K, et al. Transient monocular blindness and increased platelet aggregability treated with aspirin: A case report. Neurology 1971;21:402.Google Scholar
Harrison, MJG, Marshall, J, Meadows, JC, et al. Effect of aspirin in amaurosis fugax. Lancet 1971;2:743–744.CrossRefGoogle ScholarPubMed
Fields, WS, Lemak, N, Frankowski, R, Hardy, RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301–306.Google Scholar
Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 1978;299:53–59.Google Scholar
UK-TIA Study Group. The UK-TIA Aspirin Trial: The interim results. BMJ 1988;296:316–320.Google Scholar
The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345–1349.Google Scholar
The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. N. Engl. J. Med. 1991;325:1261–1266.Google Scholar
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.CrossRefGoogle Scholar
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;524:71–86.Google Scholar